Antengene says Australia HREC clears Phase 1 ATTRACT trial of ATG-201 in B-cell autoimmune diseasesPUBT·16 hours ago06996+2.31%
Antengene FY26 H1 returns to profit at RMB 216.35 million; revenue more than doubled to RMB 513.08 millionPUBT·Aug 21 at 05:27 AM06996+2.31%UCBJY+1.56%
Axios Names UCB a Winner of the Metro Atlanta Top Workplaces 2026 AwardPR Newswire·Aug 16 at 07:05 AMUCBJY+1.56%
UCB (ENXTBR:UCB) Stock Can Profit Momentum Calm Durability Doubts?Simplywall·Jul 31 at 02:19 PMUCBJY+1.56%
UCB: Revenue and net sales grew over 20% YoY, with upgraded 2026 guidance and strong pipeline momentumQuartr·Jul 30 at 06:41 AMUCBJY+1.56%
UCB shares fall despite guidance upgrade as investors question earnings qualityMSN·Jul 30 at 03:22 AMUCBJY+1.56%
ANTENGENE-B Expects Interim Turn to Profit with Earnings of Up to RMB238MAASTOCKS News·Jul 27 at 08:39 PM06996+2.31%UCBJY+1.56%
Antengene Signals Major Interim Profit on Oncology Licensing DealsTip Ranks·Jul 27 at 05:37 PM06996+2.31%UCBJY+1.56%
Edding Genor Realises US$48.4 Million from Sale of Candid Stake After UCB TakeoverTip Ranks·Jul 16 at 09:37 AM06998+2.05%UCBJY+1.56%
Antengene Announces Receipt of USD 60 Million Upfront Payment from UCBPR Newswire·Jul 12 at 11:00 PM06996+2.31%UCB-0.51%
UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.Unusual Whales·Jul 8 at 08:05 AMUCBJY+1.56%
UCB Data Reinforce Long-Term Promise For Weak Muscles Disorderbenzinga_article·Jul 8 at 07:46 AMUCBJY+1.56%
UCB attends EAN Congress side event on rare neurology policy, myasthenia gravis care pathwaysPUBT·Jun 30 at 05:11 AMUCBJY+1.56%
